US 12,274,708 B2
Composition for ameliorating or treating dementia containing 2′-fucosyllactose
Chul Soo Shin, Suwon-si (KR); Jong Won Yoon, Seongnam-si (KR); Seon Min Jeon, Daegu (KR); Young Ha Song, Yongin-si (KR); Jong Gil Yoo, Pyeongtaek-si (KR); and Jeong Su Bang, Ansan-si (KR)
Assigned to Advanced Protein Technologies Corp., Suwon-si (KR)
Filed by Advanced Protein Technologies Corp., Suwon-si (KR)
Filed on Nov. 14, 2023, as Appl. No. 18/508,838.
Application 18/508,838 is a continuation of application No. PCT/KR2023/013742, filed on Sep. 13, 2023.
Claims priority of application No. 10-2022-0154843 (KR), filed on Nov. 17, 2022; and application No. 10-2023-0087978 (KR), filed on Jul. 6, 2023.
Prior Publication US 2024/0173341 A1, May 30, 2024
Int. Cl. A61K 31/702 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/702 (2013.01) [A61P 25/28 (2018.01)] 2 Claims
 
1. A method for ameliorating or treating Alzheimer's dementia caused by accumulation of amyloid beta and neuroinflammation, comprising administering to a subject in need thereof a composition comprising 2′-fucosyllactose (2′-FL),
wherein the 2′-fucosyllactose (2′-FL) is orally administered at a daily dosage of 300 mg/kg to 1,200 mg/kg.